{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:34:42Z","timestamp":1789947282298,"version":"4.0.1"},"reference-count":52,"publisher":"Impact Journals, LLC","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,7,12]]},"DOI":"10.18632\/oncotarget.9949","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T12:34:23Z","timestamp":1465648463000},"page":"43974-43988","source":"Crossref","is-referenced-by-count":26,"title":["Crucial factors of the inflammatory microenvironment (IL-1\u03b2\/TNF-\u03b1\/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an <i>in vitro<\/i> study"],"prefix":"10.18632","volume":"7","author":[{"given":"Daria","family":"Sollazzo","sequence":"first","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorian","family":"Forte","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Polverelli","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Romano","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Perricone","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Ottaviani","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Luatti","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vianelli","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Catani","sequence":"additional","affiliation":[{"name":"Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology \u201cL. e A. Ser\u00e0gnoli\u201d, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,6,11]]},"reference":[{"key":"1","first-page":"415","article-title":"New pieces of a puzzle: the current biological picture of MPN","volume":"1826","author":"Levine","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms: a contemporary review","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2009.013375","article-title":"Blood cell activation in myeloproliferative neoplasms","volume":"94","author":"Alvarez-Larr\u00e0n","year":"2009","journal-title":"Haematologica"},{"key":"4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.molmed.2005.10.003","article-title":"A JAK2 mutation in myeloproliferative disorders : pathogenesis and therapeutic and scientific prospects","volume":"11","author":"Vainchenker","year":"2005","journal-title":"Trend Mol Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding and treatment strategies","volume":"29","author":"Vainchenker","year":"2011","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Bagienski","year":"2013","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/asheducation-2014.1.268","article-title":"How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?","volume":"2014","author":"Mullally","year":"2014","journal-title":"Hematology AM Soc Hematol Educ Program"},{"key":"8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR,or MPL in primary myelofibrosis","volume":"124","author":"Cavalloni","year":"2014","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1038\/ncomms7691","article-title":"Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms","volume":"6","author":"Waghorn","year":"2015","journal-title":"Nat Commun"},{"key":"10","doi-asserted-by":"publisher","first-page":"284706","DOI":"10.1155\/2015\/284706","article-title":"Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development","volume":"2015","author":"Mesa","year":"2015","journal-title":"Mediators Inflamm"},{"key":"11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","article-title":"The role of cytokines in the initiation and progression of myelofibrosis","volume":"24","author":"Hasselbalch","year":"2013","journal-title":"Cytokine Growth Factor Rev"},{"key":"12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002770050595","article-title":"Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis","volume":"78","author":"Martyr\u00e9","year":"1999","journal-title":"Ann Hematol"},{"key":"13","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood-2013-02-485888","article-title":"The Relationship Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT)","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Pardanani","year":"2011","journal-title":"J Clin Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","article-title":"Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia","volume":"98","author":"Frassoni","year":"2001","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2004-08-3238","article-title":"MPD Research Consortium. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases","volume":"105","author":"Hoffman","year":"2005","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.exphem.2007.10.001","article-title":"Altered SDF-1\/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease","volume":"36","author":"Hoffman","year":"2008","journal-title":"Exp Hematol"},{"key":"19","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood-2011-11-394775","article-title":"Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?","volume":"119","author":"Hasselbalch","year":"2012","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.leukres.2012.10.020","article-title":"Chronic Inflammation as a Promoter of Mutagenesis in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis. A Human Inflammation Model for Cancer Development","volume":"37","author":"Hasselbalch","year":"2013","journal-title":"Leuk Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/blood-2008-06-158386","article-title":"French INSERM and the European EUMNET Networks on Myelofibrosis. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence","volume":"112","author":"Le Bousse-Kerdil\u00e8s","year":"2008","journal-title":"Blood"},{"key":"22","doi-asserted-by":"publisher","first-page":"606819","DOI":"10.1155\/2015\/606819","article-title":"Inflammation as a driver of clonal evolution in Myeloproliferative Neoplasm","volume":"2015","author":"Fleischman","year":"2015","journal-title":"Mediators Inflamm"},{"key":"23","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1186\/1755-1536-5-S1-S20","article-title":"Primary myelofibrosis and the \u201cbad seeds in bad soil\u201d concept","volume":"5","author":"Le Bousse-Kerdil\u00e8s","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"24","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1182\/blood-2012-04-422378","article-title":"The sixth sense: hematopoietic stem cells detect danger through purinergic signaling","volume":"120","author":"Lemoli","year":"2012","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2141.2002.03874.x","article-title":"Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathyc primary myelofibrosis","volume":"119","author":"Novetsky","year":"2002","journal-title":"Br J Haematol"},{"key":"26","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"Tumor necrosis factor-alpha facilitates clonal expansion of JAK2V617F-positive cells in myeloproliferative neoplasms","volume":"118","author":"Silver","year":"2011","journal-title":"Blood"},{"key":"27","first-page":"1443","article-title":"P2 receptors and extracellular ATP: a novel homeostatic pathway in inflammation","volume":"3","author":"Di Virgilio","year":"2011","journal-title":"Front Biosci (Schol Ed)"},{"key":"28","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","article-title":"Biologic basis for interleukin-1 in disease","volume":"87","author":"Dinarello","year":"1996","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/sj.leu.2403457","article-title":"Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways","volume":"18","author":"Pallis","year":"2004","journal-title":"Leukemia"},{"key":"30","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/ijc.28198","article-title":"IL-1\u03b2 inhibits self-renewal capacity of dormant CD34+\/CD38- acute myelogenous leukemia cellsand","volume":"133","author":"Yokoyama","year":"2013","journal-title":"Int J Cancer"},{"issue":"512","key":"31","first-page":"78","article-title":"Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms","volume":"7","author":"M\u00e9ndez-Ferrer","year":"2014","journal-title":"Nature"},{"key":"32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1365-2141.2003.04566.x","article-title":"Quiescent CD34+ early erythroid progenitors are resistant to several erythropoietic \u2018inhibitory\u2019 cytokines; role of FLIP","volume":"123","author":"Ratajczak","year":"2003","journal-title":"Br J Haematol"},{"key":"33","doi-asserted-by":"publisher","first-page":"19414","DOI":"10.18632\/oncotarget.6838","article-title":"Novel functions of TIMPs in cell signaling","volume":"7","author":"Kim","year":"2016","journal-title":"Cancer Metastasis Rev"},{"key":"34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00018-013-1457-3","article-title":"Cytokine functions of TIMP-1","volume":"71","author":"Ries","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/BJ20131119","article-title":"TIMP-1 modulates chemotaxis of human neural stem cells through CD63 and integrin signalling","volume":"459","author":"Lee","year":"2014","journal-title":"Biochem J"},{"key":"36","first-page":"628","article-title":"Physiological relevance of erythroid-potentiating activity of TIMP","volume":"321","author":"Welgus","year":"1986","journal-title":"Nature"},{"key":"37","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.exphem.2015.07.003","article-title":"The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63PI3K\/Akt signaling","volume":"43","author":"Curti","year":"2015","journal-title":"Exp Hematol"},{"key":"38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/blood-2006-01-035634","article-title":"The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration","volume":"109","author":"Baccarani","year":"2007","journal-title":"Blood"},{"key":"39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V97.3.587","article-title":"Nucleotide receptors: an emerging family of regulatory molecole in blood cells","volume":"97","author":"Baricordi","year":"2001","journal-title":"Blood"},{"key":"40","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2004-03-0834","article-title":"Extracellular nucleotides are potent stimulators of human hematopoietic stem cellsand","volume":"104","author":"Di Virgilio","year":"2004","journal-title":"Blood"},{"key":"41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1182\/blood-2011-07-370775","article-title":"Purinergic signalling inhibits human acute myeloblastic leukemia cell proliferation, migration and engraftment in immunodeficient mice","volume":"119","author":"Salati","year":"2012","journal-title":"Blood"},{"key":"42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2010-12-327593","article-title":"Effects of the JAK2 mutation on the hemopoietic stem and progenitor compartment in human myeloproliferative neoplasms","volume":"118","author":"Huntly","year":"2011","journal-title":"Blood"},{"key":"43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.12688\/f1000research.8081","article-title":"Recent advances in understanding myelofibrosis and essential thrombocythemia","author":"Plo","year":"2016","journal-title":"F1000Res"},{"key":"44","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Courtoy","year":"2016","journal-title":"Blood"},{"key":"45","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targetingthe PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Vannucchi","year":"2013","journal-title":"J Cell Mol Med"},{"key":"46","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/jcmm.12156","article-title":"Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors","volume":"17","author":"Lee","year":"2013","journal-title":"J cell Mol Med"},{"key":"47","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Bloomfield","year":"2009","journal-title":"Blood"},{"key":"48","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1634\/stemcells.2006-0333","article-title":"Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection","volume":"24","author":"Bresadola","year":"2006","journal-title":"Stem Cells"},{"key":"49","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","article-title":"Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet\/MPN&MPNr-EuroNet (COST action BM0902) study","volume":"27","author":"Jansen","year":"2013","journal-title":"Leukemia"},{"key":"50","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/leu.2011.155","article-title":"The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories","volume":"25","author":"Iacobucci","year":"2011","journal-title":"Leukemia"},{"key":"51","volume-title":"ISCN 2009: International System of Human Cytogenetic Nomenclature","author":"Campbell","year":"2009"},{"key":"52","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus. : a refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T12:30:55Z","timestamp":1596717055000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.9949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,11]]},"references-count":52,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2016,7,12]]}},"alternative-id":["9949","27304059"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.9949","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,11]]}}}